该公司还在同时试验一种针对SARS-CoV-2、流感和RSV的联合疫苗,以及另一种针对流感和RSV的疫苗。 参考资料:MODERNA ANNOUNCES MRNA-1345, AN INVESTIGATIONAL RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE, HAS MET PRIMARY EFFICACY ENDPOINTS IN PHASE 3 TRIAL IN OLDER ADULTS 版权/免责说明:...
Moderna Announces First Participant Dosed in Phase 2/3 Study of its mRNA Respiratory Syncytial Virus (RSV)Vaccine网页链接 关于禹杭资本 Moonbay capital 禹杭资本于2017年在美国旧金山成立,2019年正式进入中国,设有美元基金和人民币基金,是一家专注于医疗创新及信息技术产业领域投资的全球性投资公司。禹杭资本...
原文出处:Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data
Since RSV causes a significant disease burden in children, mRNA-1345 is being tested in an ongoing Phase 1 trial in pediatric populations; the clinical trial is fully enrolled. Moderna has developed a respirato...
METHODS. This phase 2, randomized, observer-blind study enrolled participants into 2 age cohorts (2 to < 5 years and 5 to < 18 years). Participants aged 2 to < 5 years were healthy or had stable, chronic conditions increasing risk for RSV disease, and were randomized (1:1:1:1) to ...
Interim findings are presented from a phase 3 trial evaluating mRNA-1345 revaccination at 12 months after a primary dose in adults aged 鈮 50 years. Figure 1. METHODS. Part C of a multi-part, ongoing, phase 3 trial (NCT05330975) evaluated the safety, tolerability, and immunogenicity of ...
莫德纳预计将入组34000名参与者。(生物谷Bioon.com) 原文出处:Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data
Moderna Announces First Participant Dosed in Phase 2/3 Study of its mRNA Respiratory Syncytial Virus (RSV)Vaccinehttps://www.businesswire.com/news/home/20211118005257/en/ 关于禹杭资本 Moonbay capital 禹杭资本于2017年在美国旧金山成立,2019年正式进入中国,设有美元基金和人民币基金,是一家专注于医疗创...